Thanks in part to a really nasty flu season, GenMark Diagnostics ($GNMK) ended 2012 with a big boost in revenue. The Carlsbad, CA, company generated $9.4 million in revenue for the 2012 fourth quarter, up substantially from $2 million in revenue over the same period a year ago. For the year, GenMark booked nearly $20.5 million in revenue, a big jump from the company's $5 million in revenue generated in 2011. GenMark's $21.9 million in net losses for the year were still high, but an improvement over nearly $24 million in net losses over the previous year. GenMark's four FDA-cleared molecular diagnostic tests focus on cystic fibrosis genotyping, respiratory viruses, thrombophilia and sensitivity to warfarin. Release